X

Drug Profile

BMS 986454

Alternative Names: BMS-986454

Latest Information Update: 12 Jun 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bristol-Myers Squibb
Class
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Autoimmune disorders

Most Recent Events

12 Jun 2024 Phase-I clinical trials in Autoimmune disorders in USA (unspecified route), prior to June 2024 (Bristol-Myers Squibb pipeline, June 2024)
23 Oct 2023 Preclinical trials in Unspecified in USA (unspecified route) prior to October 2023
23 Oct 2023 Bristol-Myers Squibb plans a phase I trial in Healthy volunteers (In adults) in October 2023 (NCT06086886)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com